# A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide

> **NCT06748937** · PHASE2 · RECRUITING · sponsor: **TASK Applied Science** · enrollment: 60 (estimated)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Alpibectir 45 mg once daily (OD) plus Ethionamide 125 mg OD
- **DRUG:** Alpibectir 45 mg OD plus Ethionamide 250 mg OD
- **DRUG:** Isoniazid, rifampicin, pyrazinamide and ethambutol fixed dose combination, weight based
- **DRUG:** Alpibectir 45 mg OD plus Ethionamide 250 mg OD plus Rifampicin 10 mg/kg OD plus Ethambutol 20 mg/kg OD plus Pyrazinamide 25 mg/kg OD

## Key facts

- **NCT ID:** NCT06748937
- **Lead sponsor:** TASK Applied Science
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-03
- **Primary completion:** 2026-03-30
- **Final completion:** 2026-03-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06748937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06748937, "A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06748937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*